MVA E2
AXP000191.1 · Cancer vaccine
- Platform
- MVA
- Originator
- Instituto Mexicano del Seguro Social / Virolab
- Sponsor
- Virolab
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA
- Replication
- non replicating
- Modifications
- bovine papillomavirus E2 gene inserted into MVA
- Transgenes
- bovine papillomavirus E2
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30605254 | MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis. | Head & neck | 2019 | name in title: MVA E2 therapeutic vaccine |
| PMID 25275724 | Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. | Human gene therapy | 2014 | name in title: MVA E2 therapeutic vaccine |
| PMID 17263589 | MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2007 | name in title: MVA E2 |
| PMID 16456551 | Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. | Cancer gene therapy | 2006 | name in title: MVA E2 |
| PMID 15144573 | Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. | Human gene therapy | 2004 | name in title: MVA E2 |
| PMID 12067445 | Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. | Human gene therapy | 2002 | name in title: MVA E2 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41294662 | Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials. | Current oncology (Toronto, Ont.) | 2025 | name in abstract: MVA E2 |
| PMID 35880341 | [Clinical research progress and implications of therapeutic vaccines for cervical cancer and precancerous lesions: a qualitative systematic review]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2022 | name in abstract: MVA E2 |
| PMID 32390320 | Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. | The journal of obstetrics and gynaecology research | 2020 | name in abstract: MVA E2 |
| PMID 19225922 | Medical treatment of cervical intraepithelial neoplasia II, III: an update review. | International journal of clinical oncology | 2009 | name in abstract: MVA E2 |
| PMID 10738224 | Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. | Cancer | 2000 | name in abstract: MVA E2 |
| PMID 10999461 | A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. | Cancer immunology, immunotherapy : CII | 2000 | name in abstract: MVA E2 |
Notes
MVA encoding the bovine papillomavirus E2 protein, injected locally into HPV-associated intraepithelial lesions (intrauterine in women, intraurethral in men, at the lesion base for vulvar/anal lesions). A phase 3 study of 1,356 patients in Mexico and Venezuela (2007-2012) reported 89.4% complete lesion elimination in women; the trial was largely uncontrolled and the paper's efficacy figures are internally inconsistent. Route recorded as topical/intralesional is not in the registry's route vocabulary, so route is left empty and described here.
How to cite
MVA E2 (AXP000191.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000191.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.